The Power of Loxo Oncology at Lilly

Eli Lilly and Company  | September 18, 2020

Lilly is continually implementing new ways to accelerate research efforts in order to shorten the time it takes to discover and develop new medicines, and that includes reimagining our strategy for oncology research and development. Following the acquisition of Loxo Oncology in early 2019, we created a new organization, Loxo Oncology at Lilly, that combines the biotech mindset of Loxo Oncology with the scale and resources of Lilly to deliver meaningful new medicines for people with cancer.

Precision medicine, or the ability to target specific genomic alterations driving disease, has been a focus of Loxo Oncology since its inception and is a priority for Lilly Oncology. Combining the strengths and capabilities of both organizations has allowed us to work faster to get new therapies into the hands of the physicians and patients who need them.

For example, we recently launched a new medicine, a targeted therapy designed to inhibit a driver of tumor growth in certain cancers, in the summer of 2020, taking less than three years from when it entered clinical trials to approval and representing the most rapid timeline of any oncology medicine with multiple indications.

Together, we’re leveraging precision medicine and a growing understanding of the molecular drivers of cancer, building on Lilly Oncology’s dedication to developing and delivering innovative new medicines that will make a meaningful difference to those living with the disease.